The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy

Pancreatic ductal adenocarcinoma (PDAC) has a 5‐year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Reader, Claire S, Vallath, Sabari, Steele, Colin W, Haider, Syed, Brentnall, Adam, Desai, Ami, Moore, Kate M, Jamieson, Nigel B, Chang, David, Bailey, Peter, Scarpa, Aldo, Lawlor, Rita, Chelala, Claude, Keyse, Stephen M, Biankin, Andrew, Morton, Jennifer P, Evans, TR Jeffry, Barry, Simon T, Sansom, Owen J, Kocher, Hemant M, Marshall, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852434/
https://www.ncbi.nlm.nih.gov/pubmed/31259422
http://dx.doi.org/10.1002/path.5320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852434/
https://www.ncbi.nlm.nih.gov/pubmed/31259422
http://dx.doi.org/10.1002/path.5320

Ejemplares similares